drugset / Trial / NCT06316973
A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
Phase 1
Completed
32 enrolled
Clear Scientific, Inc.
National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.
Timeline
- Start
- 2024-02-07
- Primary completion
- 2024-05-30
- Completion
- 2024-06-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS-1103 | Unknown | 2.7 mg/kg | Intravenous |
| Subject | CS-1103 | Unknown | 8 mg/kg | Intravenous |
| Subject | CS-1103 | Unknown | 16 mg/kg | Intravenous |
| Subject | CS-1103 | Unknown | 19 mg/kg | Intravenous |